Background: The important diagnostic challenge facing the cytopathologist is whether a mesothelial proliferation on effusions represents a malignant mesothelioma (MM) or a benign mesothelial hyperplasia (MH). Here, we evaluated the diagnostic utility of BAP1 immunohistochemistry (IHC) in distinguishing between reactive and neoplastic mesothelial cells.
gene alterations by evaluating protein expression 11 . If BAP1 is mutated, nuclei of MM cells loss nuclear expression. If BAP1 gene is wild type, nuclei of MM cells retain nuclear immunostaining, as it occurs in normal/reactive mesothelial cells. So far, the BAP1 antibody has been tested primarily on biopsies. [13] [14] [15] [16] [17] [18] [19] [20] Only a few studies have used BAP1
IHC in effusion cytology samples as support in the diagnosis of MM, reporting heterogeneous ranges of BAP1 immunostaining negativity (53%-90%). 8, 9, [21] [22] [23] [24] [25] The aim of this study was to evaluate the utility of BAP1 IHC in the diagnosis of MM in effusions. To do this, we investigated the BAP1 protein expression on a large series of cell blocks from pleural/peritoneal effusions, with a definite diagnosis of MM or an uncertain diagnosis between MM and MH, and benign effusions. BAP1 immunostaining was also performed on biopsy samples with the same diagnoses to evaluate the differences between effusion and tissue samples.
| M A TE RI A L S A ND M E TH ODS
This study was designated as exempt by the ethics committee due to its retrospective nature; moreover, no protected health information Formalin-fixed paraffin-embedded (FFPE) cell blocks (n 5 74), alcoholfixed paraffin-embedded (AFPE) cell blocks (n 5 47), and FFPE biopsies (n 5 44) were identified, for a total of 165 specimens from 140
patients. In 12 patients, specimens were collected synchronously (n 5 8) or metachronously (n 5 4) from the same site. The study cohorts are summarized in Figure 1 . Patients without MM diagnosis (n 5 46)
were followed for a minimum of 12 to a maximum of 312 months.
FFPE and AFPE sections were immunostained using a manual pro- The following formulae of BAP1 testing for the outcome MM were calculated: sensitivity, defined as the probability of getting a "positive" result (BAP1-negative immunostain) in subjects with MM; specificity, defined as a proportion of subjects without MM with "negative" result (BAP1-positive immunostain); positive predictive value (PPV), defined as the probability of having MM in subjects with "positive" result (BAP1-negative immunostain); negative predictive value (NPV), defined as the probability in subjects without MM of getting a "negative" result (BAP1-positive immunostain). MM and negative for malignancy outcomes were considered after follow-up.
| RE S U L TS
The flow chart shown in Figure 1 points up the grouping of cases by diseases, considering initial diagnosis and follow-up diagnosis, which was not based on BAP1 results.
BAP1 staining was evaluated on 158 samples after excluding samples without an internal control (n 5 7). We observed that AFPE cell block sections resulted poorly or nonspecifically stained due to a high background staining. After fixation with formalin, AFPE sections resulted suitable to be assessed for BAP1 immunostaining. Comparing the intensity of stain in the two cohorts (AFPE undergoing formalin In the subset of specimens with an uncertain diagnosis between MM and MH (n 5 15, in 11 subjects), seven retained BAP1 expression (considering effusion and biopsy samples together). Of these BAP1-positive samples, three were MM and three were MH at follow-up (5 subjects).
Of the remaining BAP1-negative samples, all referred to MM (6 subjects). In the subset of specimens with an initial diagnosis of MH (reactive effusion), the majority retained BAP1 staining ( Figure 5) ; none developed MM. Only 4 cases showed loss of BAP1 nuclear expression;
these were MM at follow-up. 
| D ISC USSION
Our study confirms BAP1 IHC as useful tool in effusions that are suspicious for MM, when the immunoreaction is negative. Being BAP1 protein a tumor suppressor, the loss of nuclear BAP1 expression is an index of malignancy, and it does exclude a benign diagnosis. Therefore, BAP1-negative nuclear staining represents a valid ancillary test in the context of a differential diagnosis between MM and MH, in combination to a variety of IHC markers that separate benign from malignant mesothelial cells. In our samples with an uncertain diagnosis between MM and MH, the loss of BAP1 was helpful in supporting the hypothesis of MM. Indeed, all BAP1-negative cases were proved to be certain cases of MM at follow-up. Considering our results by specimen type, we noted that effusions showed loss of BAP1 expression more frequently and with a higher sensitivity than biopsies (76% vs 48.7%). The difference in sensitivity among sample types is because effusion specimens were mainly epithelial MM, whereas among biopsy specimens, there were also nonepithelial MM, as previously reported. 23 As well, the 100% specificity for BAP1 has been similarly reported in a few studies. 8, 23 However, other studies reported lower specificity. For instance, Andrici et al. 9 reported 95% specificity (interpreted by them as more likely due to artefactual negative staining), and Walts et al. (Table 1) , specificity would be 88.6% in our case series (by excluding from the formulae cases with an initial diagnosis uncertain between MM and MH).
We believe that in case of BAP1 loss, BAP1 immunostain adds value to the diagnosis of MM by cytology alone. The PPV value, that 1 is the probability that MM is present when the test is positive (BAP1 staining negative) is 100% (Table 3) . However, we want to bring to light early. 27 Although our case series is small, we are not aware of previous studies exploring BAP1 expression in methacronous samples.
Considering the final diagnosis of MM cases and regardless of specimen type, the difference in BAP1 negativity between epithelial and nonepithelial variants (71% vs 10%) is in line with other studies related to MM 13, 20 or to other tumors, as uveal melanoma. 28 Regarding the site of MM, peritoneal tumors showed a lower percentage of BAP1 negativity compared to pleural tumors (66% vs 71%, respectively), at variance with previous studies 16 ; however, this difference is not relevant. The finding of a positive BAP1 IHC result does not exclude a MM diagnosis, given that not all MMs harbor alterations of the BAP1 gene; moreover, it does not distinguish between MM and MH. NPV value, probability that the disease is not present when the test is negative (BAP1 positive), in our study is about 50% ( Table 3) .
As expected, a minority of epithelial MM retained BAP1 staining.
This agrees with the reported frequency of BAP1 mutations. In these cases, some investigators recommend to use CDKN2A(p16) FISH 14 or EZH2 IHC. 22 The evaluation of BAP1 immunostaining in effusion samples is dif- propose a score according to the percentage of positive tumor cells: 0 (<10%), 1 (10%-49%), 2 (50%-90%), 3 (>90%). 22 We consider that the evaluation of nuclear positivity may be insidious when there are numerous reactive mesothelial cells concealing rare neoplastic mesothelial cells.
We noted the loss of nuclear BAP1 staining in association with cytoplasmic BAP1 retention in several specimens. The reasons of this finding are not well defined. 19, 29, 30 One explanation is that somatic alterations in exons coding for nuclear localization signals led to BAP1 protein delocalization. 29 BAP1 cytoplasmic positivity could be used as positive control in cytological samples, when internal control cells are absent.
In effusion specimens, BAP1 IHC negativity may be a very useful tool in distinguishing MM from MH in combination to a variety of IHC markers that separate benign from malignant mesothelial cells without the aid of p16 FISH, which is not available in many cytology laboratories. In contrast to the role of BAP1 as diagnostic tool, its prognostic role is not completely explained. A recent meta-analysis has shown that somatic alterations in BAP1 gene are associated with poor prognosis in many cancers, except for MM. 31 In our series, subjects with BAP1-negative MM had a slightly but not significant longer survival than subject with BAP1-positive MM (13.5 months, data not shown).
While BAP1 IHC has been applied primarily on biopsies, [13] [14] [15] [16] [17] [18] [19] [20] our study has contributed to widen the number of cytological samples tested for the antibody BAP1 in effusions in relation to MM and its mimics.
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